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Abstract 
 
Aim 
To increase awareness of the prevalence and cost of psychiatric and neurological disorders 
(brain disorders) in the UK. 
 
Method 
UK data for 18 brain disorders were extracted from a systematic review of European 
epidemiological data and prevalence rates and the costs of each disorder were summarised 
(2010 values).   
 
Results 
There were approximately 45 million cases of brain disorders in the UK, with a cost of €134 
billion per annum. The most prevalent were headache, anxiety disorders, sleep disorders, 
mood disorders and somatoform disorders. However, the five most costly disorders (€ 
million) were: dementia: €22,164; psychotic disorders: €16,717; mood disorders: €19,238; 
addiction: €11,719; anxiety disorders: €11,687. Apart from psychosis, these five disorders 
ranked amongst those with the lowest direct medical expenditure per subject (<€3000). The 
approximate breakdown of costs was: 50% indirect costs, 25% direct non-medical and 25% 
direct health-care costs.  
 
Discussion 
The prevalence and cost of UK brain disorders is likely to increase given the ageing 
population. Translational neurosciences research has the potential to develop more effective 
treatments but is underfunded. Addressing the clinical and economic challenges posed by 
brain disorders requires a coordinated effort at an EU and national level to transform the 
current scientific, healthcare and educational agenda. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background 
 
No group of chronic diseases burdens the world more than mental illnesses (World Health 
Organisation (WHO), 2008). Numerous epidemiological studies on mental disorders 
throughout the world have shown that in each year about one third of the adult population 
suffers from a mental disorder (Kessler et al, 2009). Yet, less than one third receive any form 
of treatment, suggesting a considerable level of unmet need (Kessler et al, 2009, Wittchen et 
al, 2010). Neurological disorders, including stroke and dementia, are usually classified 
separately and involve additional substantial costs.   
 
Mental and neurological illnesses, taken together comprise “disorders of the brain” and, 
according to current estimates, these brain disorders account for approximately 13% of 
global disease prevalence, surpassing both cardiovascular diseases and cancer (Collins et 
al, 2011). The total EU healthcare burden of disorders of the brain represents the largest 
contributor to the “all cause morbidity” burden as measured by disability-adjusted life years 
(DALYs) and is arguably the number one economic challenge for European healthcare now 
and for the future (Gustavsson et al, 2011a). Moreover, the Global Burden of Disease 
studies that cover all disease groups and injury categories (Murray and Lopez, 1997; WHO, 
2002; WHO, 2008), demonstrate that increasingly higher proportions of the global burden of 
disease will be attributed to brain disorders over time.  
 
With scarce resources available to invest into health research, difficult choices have to be 
made on which diseases to prioritize. Cost-of-illness studies can help to inform research 
priorities by providing estimates of the economic burden of particular health problems 
(Luengo-Fernandez et al, 2012). According to a 2006 UK governmental review (Cooksey D, 
2006), the impact of diseases on the population and economy should be used to help 
determine health research priorities. Therefore, by applying cost of illness studies 
consistently across several diseases, it may be possible to rank diseases according to their 
economic burden and help plan the allocation of future research funds towards those 
diseases with the greatest burden (Luengo-Fernandez et al., 2012). 
 
Careful attention to indirect costs is required in any study that attempts to analyse the true 
burden of individual disorders. Compared with somatic diseases, brain disorders involve 
disproportionally high indirect costs (i.e. lost production due to work absence or early 
retirement) and relatively low direct health and social care costs (Collins et al., 2011; Murray 
and Lopez, 1996; Prince et al, 2007; WHO, 2008; Wittchen and Jacobi, 2005). This means 
that the application of more effective treatment has the potential to considerably reduce the 
overall economic burden to society and improve patient quality of life, over and above any 
reductions in healthcare costs. Thus, there is a clear argument for investing in research that 
leads to a better understanding of how to most effectively prevent, diagnose, treat and 
manage brain diseases.  
 
Research into the causes and the treatment of brain disorders and the allocation of 
appropriate mental health treatment resources and care have been hampered over the 
years. Impediments include the marginalization and stigmatization of mental illness as well 
as inter-disciplinary fragmentation of research and practice (Wittchen et al., 2011, Prince et 
al., 2007; Klin and Lemish, 2008). There is also an impending crisis in drug-development 
(Insel and Sahakian, 2012), which requires a major overhaul of translational research into 
mental health. The worldwide withdrawal of major pharmaceutical companies from key areas 
of preclinical and clinical neuroscience research (Nutt and Goodwin, 2011) and the trend for 
industrial research to move away from the UK and Europe, are the more recent and pressing 
threat to prospects for the advancement of treatment for brain disorders in the UK. It is 
imperative to redirect and coordinate the UK national research strategy, including 
governmental policy, industrial partnerships and the third sector contributions. However, to 
do so successfully requires current and relevant data regarding the whole cost and burden of 
brain disorders. 
 
Prevalence estimates for health services planning have often been derived from the World 
Health Organization’s Burden of Disease studies (Murray and Lopez, 1996; WHO, 2002; 
WHO, 2008), and there has been a relative shortage of systematic data on the impairments 
and disabilities associated with specific brain disorders across the UK. Estimates derived 
from global data are of relatively limited value for UK research and health planning, as they 
are heavily influenced by the most populous countries and regions.  In addition, collating 
data from diverse populations with varying disease epidemiology and substantially different 
socio-economic and health care systems obscures country specific patterns. National and 
regional specific data are likely to be of more value for planning.  
 
In 2011, the European Brain Council (EBC) together with the European College of 
Neuropsychopharmacology (ECNP), extended and updated an earlier study, first performed 
in 2004, estimating the comprehensive cost and burden of all disorders of the brain in 
Europe (Andlin-Sobocki et al., 2005; Wittchen and Jacobi, 2005, Wittchen et al., 2011, 
Gustavsson et al., 2011a). Mental and neurological illness data derived from 30 European 
countries, including the UK, were used to calculate and estimate the patterns and costs of 
treatment and the health economic implications in terms of total direct and indirect costs for 
EU nations (Andlin-Sobocki et al., 2005; Wittchen and Jacobi, 2005). Here we present a 
summary of the epidemiological data for the size, burden and cost of disorders of the brain 
specifically pertaining to the UK, derived from the EBC/ECNP 2011 studies (Wittchen et al., 
2011, Gustavsson et al., 2011a).  
 
Our overarching aim is to strengthen awareness of the impact and cost of disorders of the 
brain in the UK, including the indirect costs, to focus attention on the scope for improved 
collaborative research and treatment development across the fields of mental and 
neurological illness and to identify those areas of most need. We attempt to identify the 
illnesses that contribute most in terms of global health burden, as well as those for which 
improvement in available treatment might prove most fruitful in health-economic and quality-
of life terms, as a guide for future research prioritisation within the NHS. Finally, we offer 
constructive suggestions, based upon some promising recent health initiatives e.g. in the 
field of stroke and dementia, that we believe could make a significant difference in moving 
the field forward. 
 
Objectives 
 
The objective of this analysis was to estimate for the UK, in 2010, (1) the number of 
individuals with disorders of the brain; (2) the total cost per person related to each brain 
disorder, classified according to direct and indirect costs and (3) the total cost per brain 
disorder for the UK economy. 
 
Methods  
 
The EBC/ECNP studies (Wittchen et al 2011, Gustavsson et al 2011a) were designed and 
managed by prominent epidemiologists and health economists. A comprehensive and 
systematic review of epidemiological data was conducted by panels of European experts; 
UK summary data was extracted from the European database by members of the EBC team 
and reviewed by the authors of this paper, including clinicians with expertise in a broad 
diversity of brain disorders and their epidemiology (NF, PMH, EJ, JBR, DN, AHY) as well as 
experts in preclinical neuroscience (BJS) statistics (DW, LC) and health economics (BG).  
 
Details of the EBC study methodology have already been published (Wittchen et al., 2011, 
Gustavsson et al., 2011a). In summary, a stepwise multi-method study approach was 
adopted 
consisting of (a) iterative literature searches for epidemiological publications and subsequent 
data analyses of published material, (b) reanalyses of existing accessible epidemiological 
data sets and (c) structured expert inquiries and a questionnaire survey with experts in all 
EU countries. Only those studies conducted in community samples and reporting prevalence 
estimates for established diagnoses of mental disorders (according to criteria of DSM-III 
(APA, 1980), DSM-IIIR (APA, 1987) or DSM-IV (APA, 1994); or ICD-10, (World Health 
Organization, 1993) or those using at least instruments with explicit diagnostic criteria that 
allow such inferences, were considered. The results produced consolidated best estimates 
for the EU total population in the year 2010 for (1) the 12 month prevalence of mental and 
neurological disorders covering as far as possible all major disorders for children and 
adolescents (2–17 years), adults (18–65 years), and the elderly (65+ years); (2) the number 
of persons affected by each diagnosis. The consolidated size and burden data were further 
used for (3) comprehensive health economic analyses, including cost-modelling for all 
conditions covered. Table one details the sources from which all cost information was 
obtained for the UK. 
 
Table one; Summary of Cost Data as sourced from Gustavsson et al, 2011a 
 
  
The total cost of a disorder in the UK was calculated by combining epidemiological (number 
of patients) and economic data (cost per patient), using a prevalence-based approach which 
multiplied the total number of UK persons affected by a disorder in a 12-month period 
(2010), with their mean cost in the same year. There are several approaches to assess the 
cost of a defined disease. This study considered the costs of all resources used or lost due 
to the disease, irrespective of who the paying organisations are (employers, families, 
Department of Work and Pensions, National Health Service etc.). This perspective is 
arguably the most relevant for decision makers, whose main interest is the welfare of society 
as a whole. It is also the relevant perspective for judging if all costs are included (though it is 
important to include each cost item only once in order to avoid double counting). Costs are 
presented in three main categories: a) direct health care costs (i.e. all goods and services 
related to the prevention, diagnosis and treatment of a disorder; e.g. physician visits, 
hospitalizations and pharmaceuticals), b) direct non-medical costs (i.e. other goods and 
services related to the disorder; e.g. social services, special accommodation and informal 
care), and c) indirect costs (i.e. lost production due to work absence or early retirement). 
Cost-items excluded from the estimates, due to the lack of data or lack of consistent 
methods on how to value and report these costs, included indirect costs due to premature 
mortality, intangible costs (i.e. the monetary value of suffering from a disorder), and costs of 
crime caused by e.g. addiction. Costs related to research were also excluded because they 
are not considered to be caused by the disorder per se, but rather as an investment aimed at 
reducing the costs in the future. Moreover, to a large extent, research costs will likely be 
reflected in the prices of potential treatment interventions coming out of this research.	  	  	  
A “bottom-up” analysis of costs was applied and the study identified as far as possible 
patient level data (from UK literature) on annual direct and indirect costs incurred for each 
disorder (e.g. by ascertaining cost items from interview, questionnaire or review of medical 
records); the mean cost per person was then multiplied by the estimated number of UK-
affected persons to obtain an approximation of the total cost. Adjustments were made to 
avoid inflated estimates related to the specific sample characteristics. However, in the case 
that no such data was available for a disorder, estimates from “top–down” national or 
regional statistics on the total costs of a group of disorders were used. Existing UK-specific 
data for each disorder was applied to a model that additionally adjusted cost estimates to 
2010 values and to the total UK population with the disorder where the available treatment-
cost estimates only referred to a patient-subset, and allowed extrapolation from other 
countries to fill data gaps (see Gustavsson et al, 2011a for further details).	   
 
 
Results 
 
Primary ‘patient-level’ UK prevalence data (from literature) was available for the majority of 
brain disorders. Where prevalence data from the UK was unavailable, data from other EU 
countries was used; anxiety disorders (Iceland, Norway & Switzerland), psychosis and 
eating disorder (Germany), stroke (Iceland, Norway & Sweden), headache (Central Europe), 
brain tumour (Norway & Sweden), somatoform disorder (Central Europe) and some sleep 
(Norway) and neuromuscular disorders (Central Europe). Table two lists the disorders 
included in the study.  
 
Table two. List of disorders (ICD-10 codes) as sourced from Gustavsson et al. 2011 
 
UK prevalence of disorders of the brain 
 
Figure one illustrates the estimated 12 month UK prevalence of disorders of the brain 
included in this study in 2010. The estimated total amounted to roughly 45 million diagnosed 
cases; ranging between 26,000 cases of brain tumour and 18 million cases of headache. 
There were greater than 5 million cases of anxiety disorder (8,196, 000 (18.17% of UK 
population)) and sleep disorder (5,268,0000 (11.68%)) and greater than one million cases of 
addiction (1,878,000 (4.16%)), other mood disorder (3,937,000 (8.73%)) and somatoform 
disorder (2,396,000 (5.31%)). 
 
 
 
Figure one; estimated 12 month UK prevalence of disorders of the brain  
 
 
UK cost of disorders of the brain 
 
The total UK cost of disorders of the brain in 2010 was estimated at €134,476 million. 
Indirect costs associated with patients' productivity losses constituted by far the largest 
component of the total cost (€62,346 million), comprising 46.4% of the overall cost, whereas 
the remainder of the cost was divided into 26.8% each for direct non-medical (€36,077 
million) and direct health-care (€36,053 million) costs.  
 
Cost per subject  
 
On average, the estimated UK per subject cost of brain disorders was €3,126, but varied 
widely according to diagnosis, ranging between €391 for headache and €42,000 for 
neuromuscular disorders (figure two). Disorders for which the per subject total cost 
exceeded €20,000 included neuromuscular disorders, brain tumour, dementia, multiple 
sclerosis, psychosis and Parkinson’s disease. Direct medical expenditure was highest per 
subject for brain tumour, neuromuscular disorders, mental retardation, multiple sclerosis, 
psychosis and stroke, whereas the highest direct non-medical costs were associated with 
dementia, multiple sclerosis and Parkinson’s disease. Neuromuscular disorders, psychosis 
and brain tumour were also associated with the highest individual indirect costs.  
 
Data on direct non-medical costs for brain tumour, headache, psychotic disorders, sleep 
disorders and somatoform disorders were missing from the original paper. Data on indirect 
costs for child/adolescent disorders, dementia and mental retardation were also missing 
from the original survey. Therefore these were not included in the analysis. 
 
 
 
Figure two; UK per subject cost of brain disorders  
 
 
 
Total cost 
 
Taking account of the prevalence data, the total 2010 cost (in million € purchasing power 
parity (PPP) of the individual disorders of the brain included in this study, ranked in order of 
magnitude, was as follows ( figure three): dementia: €22,164; psychotic disorders: €16,717; 
mood disorders: €19,238; addiction: €11,719; anxiety disorders: €11,687; personality 
disorders:€4,918; child/adolescent disorders: €2,757; stroke: €8,490; headache: €7,119; 
mental retardation: €5,975; traumatic brain injury: €5,658; sleep disorders: €5,630; 
somatoform disorder: €3,514; multiple sclerosis: €2,700; Parkinson's disease: €2,361; 
epilepsy: €1,638; neuromuscular disorders: €1,301; brain tumour: €766; eating disorders: 
€124. Thus, the five overall most costly disorders of the brain were dementia, mood disorder, 
psychotic disorder, anxiety disorder and addiction. The cost of these disorders was the 
highest despite having missing data on some cost types. It is noteworthy that, apart from 
psychosis, these most costly disorders ranked amongst those disorders with the lowest per 
subject direct medical expenditure (<€3,000 per subject; figure two). 
 
Figure three; total UK cost of individual brain disorders  
 
  
Discussion 
 
Our report provides the most recent and comprehensive estimate of total costs for brain 
disorders, and brings together disorders that traditionally may have been separated into 
psychiatric and neurological specialties. We believe that a coordinated approach to disorders 
of the brain needs to be adopted, with comparable methodologies for both mental and 
neurological illness. This recognises that many disorders (e.g. dementia, somatoform 
disorders, epilepsy) span both neurological and psychiatric domains, in healthcare, 
neuroscience and pharmaceutical research. The DOH have also emphasised the need for 
“parity of esteem” between mental and physical health services (DOH, 2011). 
 
The originating study (Gustavsson et al., 2011a) was based on the best currently available 
European data, applying a consistent methodology across a broad range of brain disorders. 
The model also enabled extrapolation to those disorders where no primary UK data could be 
found. We estimated the total annual cost of disorders of the brain in the UK in 2010 at 
approximately €134 billion. As expected, indirect costs associated with lost productivity 
constituted approximately 50% of the total burden with direct healthcare and non-medical 
costs each comprising just over 25% of the budget (around €36 billion each). This contrasts 
with EU-wide data for brain disorders, in which direct costs constitute the majority (60%) of 
the costs (37% direct healthcare costs and 23% direct non-medical costs) (Gustavsson et 
al., 2011a), implying a relative deficit in UK investment in direct medical care.  
 
The shortage of primary data for some disorders is an important source of uncertainty in 
these estimates (Gustavsson et al., 2011a) and may imply over, or under-estimates in some 
cases, including anxiety disorders and psychosis. In addition, the costs associated with early 
mortality were not included in the analysis. Although for some conditions these costs would  
be minimal, e.g. dementia, for others such as stroke, traumatic brain injury and tumours 
these productivity costs may be considerable, especially at the ‘cost per subject with the 
condition’ level. The exclusion of these costs also means that the results from this study may 
not be directly comparable with others that have included them e.g. Luengo-Fernandez et al. 
(2012). Moreover, there are still remaining chronic and highly disabling disorders (e.g. body 
dysmorphic disorder) that could not be included in the analysis due to further limitations in 
the available data. Therefore, our estimate of the total cost of the disorders of the brain in the 
UK could be viewed as conservative. Indeed, our figure for the total annual UK cost 
associated with brain disorders (€134 billion) is broadly consistent with an earlier 
independent estimate from the DOH, which was itself largely based on extrapolation to the 
UK from global estimates (e.g. WHO 2008), which estimated the total annual economic costs 
of mental illness (excluding neurological illness) in England alone to be £105 billion (DOH 
2011). However, it should be noted that this figure included an estimate for reduced quality 
of life, in addition to direct costs of services and lost productivity at work.  
 
With regards annual direct expenditure, our estimates (€36 billion each for direct healthcare 
and non-medical services) are also compatible with available independent DOH estimates of 
direct expenditure. For example, in 2008/9, the NHS spent 10.8% of its annual secondary 
healthcare budget on mental illness alone (excluding neurological disorders), amounting to 
£10.4 billion (DOH, 2010a). Extended service costs for mental illness in England, which 
included NHS, social and informal care costs, amounted to the larger sum of £22.5 billion in 
2007 (McCrone et al., 2008).  
 
How then do the economic costs of disorders of the brain compare with those related to 
other costly somatic diseases? The DOH (2011) estimated mental ill health to be the single 
largest cause of disability in the UK, contributing up to 22.8% of the total burden, compared 
with 15.9% for cancer and 16.2% for cardiovascular disease. More recently, Luengo-
Fernandez et al., (2012) estimated the relative 2007-8 UK health care and non-health care 
costs of dementia, stroke, cancer and coronary heart disease (CHD), representing the four 
leading causes of disability and mortality in Europe. The costs placed by dementia on the 
social care system alone (£9.3 billion) far outweighed the social care costs of cancer, CHD 
and stroke. Combining the annual costs of health and social care, dementia cost £10.5 
billion, compared to £4.5 billion for cancer, £2.7 billion for stroke and £2.3 billion for CHD. 
After combining health and social care, informal care and productivity losses, dementia also 
had the highest annual cost at £23 billion, followed by cancer (£12 billion), CHD (£8 billion) 
and stroke (£5 billion). Yet, importantly, dementia was estimated to have the lowest direct 
health care costs (£1.2 billion), compared to £4.0 billion for cancer, £2.2 billion for CHD and 
£1.6 billion for stroke.  
 
In this study, 2010 expenditure on direct medical and non-medical care of disorders of the 
brain was also low relative to the high indirect costs, especially for the common disorders of 
the brain for which the total cost to society is the highest (dementia, mood disorder, 
psychosis, anxiety disorder and addiction). However, it is precisely these same disorders for 
which UK translational neurosciences research has the realistic potential to produce 
transformative therapeutic advances (Insel and Sahakian, 2012), provided that public and 
commercial investment in research are prioritised. Moreover despite potential constriction on 
health budgets, it is critically important that research, evaluation and innovation in mental 
disorders are recognised, in order to “learn what works and what does not” and to 
disseminate this evidence into clinically effective and cost effective practice (DOH 2011).  
According to UK government recommendations (Cooksey et al., 2006), health research 
priorities should be informed by an assessment of the impact of disease on the population 
and economy. However, according to a study of 2007-8 research expenditure (Luengo-
Fernandez et al., 2012), by far the majority of health research funding in the UK has 
historically been directed towards cancer (total research expenditure = £590 million; 71%) 
and research spending on dementia (£50 million; 6%) and stroke (£23 million; 4%) has been 
comparatively seriously underfunded. In terms of economic burden, for every £1 million of 
health and social care costs attributable to each disease, cancer received £129 269 in 
research funding, CHD received £73 153, stroke received £8745 and dementia received just 
£4882. The reasons for these disparities are not well understood and likely to be complex 
They may include ignorance of the magnitude of brain disorders, disproportionate fear of 
some diseases that leads to much greater charitable giving, an historical sense of tolerance 
or therapeutic nihilism for some disorders, and stigma over mental health problems. 
The disparity in funding has recently been recognised and strategies have been initiated to 
address the NHS provision for stroke and dementia care based on translational research 
findings. For example, hyper-acute units are currently being established throughout England 
based on the finding that early thrombolysis can prevent completed stroke (DOH, 2010b). 
The 2012 ‘Prime Minister’s challenge on dementia’ (DOH, 2012) aims to double dementia 
research funding by 2015 and emphasises both translational as well as basic neuroscience 
research, through the Medical Research Council, National Institute for Health Research and 
coordination of partnerships with industry.	  The Wellcome Trust Neurodegenerative Diseases 
Initiative additionally focuses multidisciplinary research on the causes, early diagnosis and 
therapeutic interventions for neurodegenerative diseases including Alzheimer's disease, 
fronto-temporal dementia, Parkinson's disease and motor neurone disease 
(http://www.wellcome.ac.uk/Funding/Biomedical-science/Funded-projects/Major-
initiatives/Neurodegenerative-Diseases-Initiative/index.htm).  
 
Looking to the future, we see that for the UK and for Europe as a whole (Gustavsson et al., 
2011a), the health economic burden of disorders of the brain are likely to constitute the 
number one economic challenge for health care. The current estimates refer to 2010, but the 
costs over the next 20 years will not only stem from inflation, but also major increase in the 
disease burden associated with an ageing population.  For example, the prevalence of 
dementia, associated with the highest total costs to the UK, is forecast to double over the 
next 30 years (Alzheimer’s Society, 2007).  
 
With the total costs of disorders of the brain at €134 billion, and the additional prospect of an 
ageing population, it is clear that the UK must build upon the recent positive developments in 
the field of dementia and stroke and commit to a radical program of research, innovation and 
investment for prevention and cost-effective treatment focussing on those brain disorders 
that are known to be the most costly for society, including dementia, mood disorder, 
psychosis, anxiety disorder and addiction. This not only calls for a review of government 
policy, but attention by all stakeholder groups, including industrial partners, patient 
representative organisations, educational establishments and the principal research funding 
bodies. To address the challenges and major economic threat posed by disorders of the 
brain, a transformation in knowledge and policy is required. To achieve this, it is necessary 
to develop a coordinated plan of action, at an EU and national level, to revitalise and 
transform the current scientific, healthcare and educational agenda. Running from 2014 to 
2020, and with a dedicated budget of € 24 598 to strengthen top-level research in science 
aimed at improving EU productivity, Horizon 2020 - the EU’s new programme for research 
and innovation, could provide a pivotal role for enacting some of these changes.   
 
Recommendations 
  
1. Given the cost of brain disorders, which are frequently chronic and relapsing, greater 
emphasis needs to be placed on prevention, early detection and early effective treatment. 
 
2. There have been several new initiatives in the UK and globally by governments and 
charities to address the underlying pathological processes, the translational models and new 
treatments for Alzheimer’s disease e.g. the Prime Minister’s challenge, revised strategic 
priorities at the MRC, NIHR and the Wellcome Trust, as well as National research 
coordination via DenDRON and the Biomedical Research Centres in Dementia. Similar 
initiatives for the high cost areas of mood disorders and psychotic disorders would greatly 
facilitate rapid advances in these areas. New developments at a European level e.g. 
increasing the emphasis on brain disorders research under Horizon 2020, and in the NHS 
research directorate e.g. networks such as the Mental Health Research Networks should be 
encouraged and facilitated 
 
3. Screening for dementia e.g. via the new NHS CQUIN screening of hospital admissions 
over 75years of age, is increasingly common, though these NHS initiatives are sometimes 
transient and are yet to be proven to be effective.   Given that mental health disorders 
disproportionately affect the young, there is a rationale for extending screening for common 
mental health disorders into adolescence and young adults in order to be able to treat more 
effectively and earlier. 
 
4. Despite the prevalence of disorders of the brain, there is still severe stigma. Working with 
charities, patient advocacy groups and the media to reduce stigma will be important to 
facilitate patients seeking early treatment and thereby improving their functional outcome 
and wellbeing. This is particularly critical as some of these vulnerable patients are unable to 
advocate for themselves.  
 
5. Private-public partnerships should be encouraged to promote novel drug development 
and to rapidly bring treatments to patients with brain disorders.  
 
6. Efforts to remove hurdles to research must be supported at governmental level, such as 
removing inappropriate regulations within the European Clinical Trials Directive (2001/20/ec) 
or implementing faster and simpler processes for approval and governance of translational 
research.  
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Disorder Author Year Data.Source
Anxiety Jacobi'et'al. 2002 Germany
Priebe'et'al. 2009 UK
Priebe'et'al. 2010 UK
Addiction Balakrishnan'et'al. 2009 UK
Godfrey'et'al. 2004 UK
Brain.Tumours Blomqvist'et'al. 1996 Sweden
Wasserfallen'et'al. 2005 Switzerland
Dementia Gustavsson'et'al. 2011 UK
Wolstenholme'et'al. 2002 UK
Epilepsy Cockerell'et'al. 1994 UK
Jacoby'et'al. 1998 UK
Swingler'et'al. 1994 UK
Van'Hout'et'al. 1997 UK
Headache Linde'et'al. 2012 EU
Mood.Disorders Das'et'al. 2002 UK
Thomas'et'al. 2003 UK
Multiple.Sclerosis Kobelt'et'al. 2006 UK
Parkinsons McCrone'et'al. 2007 UK
Psychosis Heider'et'al. 2009 UK
Bebbington'et'al. 2005 UK
Stroke LuengoTFernandez'et'al. 2009 UK
Traumatic.Brain.Injury Morris'et'al. 2008 UK
Polinder'et'al. 2005 UK
Child.&.Adolescent.disorders Knapp'et'al. 2009 UK
HakkaartTvan'et'al. 2007 Holland
Romeo'et'al. 2006 UK
Mental.Retardation Polder'et'al. 2002 Holland
Eating.Disorders Krauth'et'al. 2002 Germany
Personality.Disorders Van'Asselt'et'al. 2007 Holland
Soeteman'et'al. 2008 Holland
Sleep.Disorders GodetTCayré 2006 France
Leger'et'al. 1999 France
Jennum'et'al. 2009 Denmark
Jennum'et'al. 2010 Denmark
Jennum'et'al. 2011 Denmark
Neuromuscular.Disorders Espérou'et'al. 2000 France
MahdiTRogers'et'al. 2009 UK
AccessEconomics 2007 Australia
Schepelmann'et'al. 2010 Germany
Somatoform.Disorders Jacobi'et'al. 2002 Germany
 Table two. List of disorders (ICD-10 codes) as sourced from Gustavsson et al. 2011 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disorders ICD*10-codes
Child/adolescent-disorders-
Hyperkinetic-disorders/ADHD F90.x
Conduct-disorder F91.x
Pervasive-developmental-disorders-/-autism- F84.x
Personality-disorders
Dissocial-PD F60.2
Emotionally-unstable-PD- F60.3
Dementia F00*F03
Headache G44
Mood-disorders-
Unipolar/major-depression- F32,-F33
Bipolar-disorders F30,-F31
Neuromuscular-disorders F50.2
Brain-tumor- C70*72
D32*33
D42*43
Traumatic-brain-injury S06
Psychotic-disorders-
Schizophrenia-and-other-psychotic- F2x
disorders-and-syndromes
Multiple-sclerosis G35
Addiction
Alcohol-dependence F10.2
Opioid-dependence F11.2
Cannabis-dependence- F12.2
Somatoform-disorder-Epilepsy F45
Epilepsy G40
Parkinson's-disease G20
Sleep-disorders-
Nonorganic-insomnia F51.x
Hypersomnia G47.1
Narcolepsy G47.3
Sleep-apnea- G47.4
Anxiety-disorders
Panic-disorder F41.0
Agoraphobia F40.0
Social-phobia F40.1
Generalized-anxiety-disorder-(GAD) F41.1
Specific-phobias- F40.2
Obsessive-compulsive-disorder-(OCD)- F42
Posttraumatic-stress-disorder-(PTSD) F43.1
Stroke 161,-163,-164
167
Mental-retardation F70*F79
Eating-disorders-
Anorexia-nervosa/atypical-AN- F50.0,-F50.1
Bulimia-nervosa/atypical-BN- F50.2,-F50.3
Figure one. Estimated 12 month UK prevalence of disorders of the brain  
 
 
 
 
Figure two; UK per subject cost of brain disorders  
 
 
 
Figure three; total UK cost of individual brain disorders  
 
 
